Alex Denner has made his first public move at The Medicines Company since consolidating power on the board — and it’s a big one.
Clive Meanwell passing the CEO role and his board seat to Merck vet Mark Timney, leaving a position he’s occupied for the better part of the company’s 22-year history.
He’s not out entirely. In the newly-created role of chief innovation officer, he is tasked with supporting the ongoing development of inclisiran — the biotech’s experimental LDL-lowering RNAi therapy in-licensed from Alnylam.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,700+ biopharma pros who read Endpoints News by email every day.Free Subscription